The inaugural Legends of Science Oncology Symposium is taking place Friday, September 12, 2025. |
Please join us for an immersive day of scientific talks and panel discussions focusing on the future of cancer research.
Discover how UC San Diego thought leaders and industry trailblazers are revolutionizing cancer care through breakthrough therapeutics, innovative research and artificial intelligence–driven advancements in oncology. Network with internationally recognized experts who are transforming treatment and reshaping the scientific landscape.
The day ends with our Legends Cocktail Party and Networking Reception — where science meets surf. Mingle with groundbreaking researchers, academic leaders, industry experts, visionary venture capitalists and legendary surfers in a vibrant atmosphere of discovery and connection.
The Legends of Science Symposium is free for members and trainees of Moores Cancer Center. Register today!
RSVP | Download the Agenda>>>
|
Behind Every Breakthrough |
Every breakthrough begins with the courage to explore, challenge, and redefine what is possible. UC San Diego’s Behind Every Breakthrough video series spotlights physician-scientists and patients at Moores Cancer Center who are driving innovation in cancer care.
In the latest episode, hear from Ramez Eskander, MD, director of the Clinical Trials Office at Moores Cancer Center, as he shares how investment and funding are critical to transforming the future of cancer treatment and care. Watch the Episode>>>
|
Supporting Fairness and Originality in NIH Research Applications (NOT-OD-25-132) |
The NIH has released new guidance to help ensure fairness and originality in research applications, which emphasizes the responsible use of artificial intelligence. In addition, the NIH will now limit each principal investigator to no more than six grant applications per calendar year. View NIH Guidance | See FAQs>>>
|
|
|
Registration Now Open: Free Compassionate Communication Workshop Series
|
This free, skills-based program is specially designed for health care professionals, medical educators, and researchers. Through interactive sessions, participants will learn how to communicate with greater compassion—and, in turn, greater effectiveness—with patients, health care teams, medical trainees, and beyond.
|
|
|
| TNF and type I interferon crosstalk controls the fate and function of plasmacytoid dendritic cells |
Juliana Idoyaga, PhD (Cancer Biology and Signaling)
|
|
|
| Computationally unmasking each fatty acyl C=C position in complex lipids by routine LC-MS/MS lipidomics |
Edward A. Dennis, PhD (Solid Tumor Therapeutics)
|
|
|
| Increasing certainty in systems biology models using Bayesian multimodel inference |
Jin Zhang, PhD (Cancer Biology and Signaling)
|
|
|
CLINICAL TRIALS OFFICE (CTO) |
|
|
MEN2312-01: A Phase I, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
PI: Rebecca Shatsky, MD
NCT ID: NCT06638307
MK-2400-001: A Phase III, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeateProstate01)
PI: Rana McKay, MD
NCT ID: NCT06925737
S2408: A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
PI: Andrew Lowy, MD, FACS
NCT ID: NCT06807437
OR502-101: A Phase I/II Study of OR502 Alone and in Combination with Other Anticancer Agents in Subjects with Advanced Malignancies
PI: Gregory Daniels, MD, PhD
NCT ID: NCT06090266
10699: A Phase I Trial Combining Triapine with Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
PI: David Piccioni, MD, PhD
NCT ID: NCT06860594
|
|
|
FEATURED FUNDING OPPORTUNITIES
|
Funding Opportunities Available on the Moores Cancer Center Website |
Explore curated funding opportunities from federal, non-federal, limited submission and internal sources, tailored to provide support for cancer research at every stage.
|
|
|
|
